While there are many reasons for a delay in drug development, low patient participation is the most common one. Today, 72% of clinical trials fail to meet their original timelines by one month or more, and inefficient patient enrollment is a leading cause of delay. How can life sciences companies address this issue and improve patient enrollments? How can they differentiate their trials and improve patient engagement?

In this whitepaper, ZS experts share four key strategies that will help life sciences companies improve enrollment.